VIETNAM MEDIPHARM EXPO

Organiser：Vietnam VIETFAIR Time：May 6 – 9, 2026 Address： 91, Trần Hưng Đạo, Hoàn Kiếm, Hà Nội, Vietnam Exhibition hall： Cultural Friendship Palace   Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, ambulance equipment, diagnostic medical equipment and supplies, otolaryngology equipment, dental products, equipment and supplies, medical health products and equipment, technical equipment for medical institutions and laboratories, medical information and technology exchange, beauty instruments, etc. Pharmaceutical Equipment: Production equipment and technology for pharmaceuticals, pharmaceutical packaging equipment, pharmaceutical packaging materials, systems for pharmaceutical production, cleaning, disinfection, and formulation, etc. Laboratory Equipment: Optical instruments and equipment, microscopes, optical image processing, electronic measuring instruments, multimeters, electron probes, electronic simulation systems, single-chip microcomputer development systems, image analysis and processing systems, etc. Analytical Instruments: Optical analytical instruments, mass spectrometers, spectrometers, chromatographs, wave spectrometers, frequency spectrometers, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, composition ...

• Source: drugdu
• 62
• February 10, 2026

Phase III clinical trial of vetcotozumab completes patient enrollment

On the morning of February 9th, China Biopharmaceutical announced on the Hong Kong Stock Exchange that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., had independently developed a Class 1 innovative drug.Vitectumomarab (development code: LM-302, abbreviated as “CLDN18.2 ADC”) is undergoing a Phase III registration clinical trial (LM302-03-101) for the treatment of third-line or higher CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, and patient enrollment has been successfully completed. LM302 is the world’s first CLDN18.2 ADC drug to complete enrollment in a Phase III registration clinical trial. https://finance.eastmoney.com/a/202602093644922352.html

• Source: drugdu
• 57
• February 9, 2026

The first long-acting coagulation factor VIII, has officially entered the Chinese mainland market.

Recently, Novo Nordisk, a leading global biopharmaceutical company…We announce the official launch of Pertrol Alpha for Injection (trade name: Noyt®) in mainland China. Noyt® is the first and currently the only* approved long-acting recombinant coagulation factor VIII in my country, and has been successfully added to the new version of the National Reimbursement Drug List. The full launch of Noyt® in the mainland China market fills the gap in long-acting treatment for hemophilia A, further improves patient accessibility, and brings Chinese hemophilia A patients into a new stage of treatment. Hemophilia is an X-linked recessive inherited bleeding disorder, which can be divided into hemophilia A and hemophilia B. Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII), and patients with this condition account for approximately 80%-85% of all hemophilia cases. It requires lifelong medication, and without timely treatment, it can lead to disability and, in severe cases, ...

• Source: drugdu
• 59
• February 9, 2026

17.9 billion yuan! A top-selling topical medication emerges.

According to data from Yaozhi, from 2016 to the first three quarters of 2025, flurbiprofen gel patch (by product category) ranked among the top-selling topical preparations in domestic public medical institutions, with a cumulative sales volume of 17.859 billion yuan , becoming the ” top seller ” in the field of topical preparations for nearly ten years , and the only product with a cumulative sales volume exceeding 10 billion yuan. Note: The scope of topical preparations in this statistic covers all chemical drugs and traditional Chinese medicines approved in the Chinese market; the statistical scope is based on the product category, not the brand dimension. 01 The Growth Secret of Top Sales Performers Flurbiprofen gel patch is a prescription topical analgesic drug. Its active ingredient is flurbiprofen, which belongs to the nonsteroidal antipyretic, analgesic, and anti-inflammatory class of drugs. It exerts its analgesic, anti-inflammatory, and antipyretic effects by inhibiting ...

• Source: drugdu
• 48
• February 9, 2026

Turnaround! Generic drug giant successfully “revived”

Recently, Teva Pharmaceuticals, an Israeli multinational pharmaceutical company, released its 2025 financial report. The company achieved total revenue of $17.3 billion, a 4% year-on-year increase in US dollar terms; net profit of $1.42 billion, successfully reversing the losses of the same period in 2024; and free cash flow of $2.4 billion, a 16% year-on-year increase. Notably, Teva has achieved revenue growth for three consecutive years . Revenue from its innovative drug portfolio exceeded $3.1 billion, representing a year-on-year increase of approximately 35%, becoming the core engine driving the company’s transformation. 01 Three new drugs continue to see increased sales volume In recent years, Teva’s revenue from innovative drugs has continued to increase, from 9% in 2022 to about 18% in 2025. Image source: Teva official website Austedo (deuterated benzidine) is its most important innovative drug to date. Approved for marketing in 2017, it was the world’s first approved deuterated drug ...

• Source: drugdu
• 56
• February 9, 2026

Novartis’s first-ever autoimmune drug has been submitted for marketing approval in China.

On February 6, the CDE website showed that Novartis’ ianalumab had applied for marketing approval in China. Ilimumab, acquired by Novartis (from MorphoSys) , is a fully human monoclonal antibody targeting B-lymphocyte activating factor receptor ( BAFF-R ). It possesses a dual mechanism of action: depleting B cells and inhibiting BAFF-R. It can be used to treat various autoimmune diseases, including Sjögren’s syndrome, immune thrombocytopenic purpura (ITP), and systemic lupus erythematosus (SLE) . This drug is the first anti- BAFF-R antibody to complete Phase III trials.In the phase III NEPTUNUS-1 study , after 48 weeks of illuminumab treatment, patients with Sjögren’s syndrome had a 6.4-point reduction in the EULAR Sjögren’s Disease Activity Index (ESSDAI) score, compared to a 5.1-point reduction in the placebo group. In the phase III NEPTUNUS-2 study, patients with Sjögren’s syndrome who received irinumab treatment for 48 weeks experienced a 6.5-point reduction in their ESSDAI score, compared ...

• Source: drugdu
• 45
• February 9, 2026

A world first! A serum-free rabies vaccine is about to be launched, marking a major breakthrough in safety.

• Source: drugdu
• 49
• February 9, 2026

【EXPERT Q&A】What are the registration and regulatory (market access) requirements for Nipah virus IVD in vitro diagnostic test reagents in India, the European Union, and the WHO?

Drugdu.com expert’s response:   I. Indian Registration and Regulatory Requirements Regulatory Framework: The Indian Drugs and Cosmetics Act and related regulations (such as CDSCO guidelines) serve as the primary regulatory basis for IVD products. Classification Management: Nipah virus detection reagents are typically classified as high-risk categories and are subject to rigorous review. Technical Documentation Requirements: Complete technical documentation must be submitted, including product descriptions, performance indicators, test reports, production processes, and quality management system documents. Key information such as detection principles, targets (genes/antigens/antibodies), sample types, and batch release criteria must be provided. Clinical Trial Requirements: Clinical trials may be required, and corresponding clinical trial data must be submitted to verify the clinical performance and effectiveness of the product. Quality Management System: A quality management system compliant with ISO 13485 standards must be established, and relevant certification certificates must be submitted. Import and Sales License: Import and sales approval must be obtained from the ...

• Source: drugdu
• 56
• February 9, 2026

Kanghua Biologics Faces Formidable Challenges in mRNA Vaccine Development

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) recently filed an announcement stating that it plans to acquire 100% equity interest in Nameixin (Shanghai) Biotech Co., Ltd. (hereinafter referred to as “Nameixin”) in phases through capital increase, equity transfer and other means, thereby obtaining a complete mRNA technology platform and refining the strategic layout of its biopharmaceutical industry. “This transaction is essentially the layout of the mRNA vaccine industry by local state-owned asset investors through a listed company platform,” a pharmaceutical industry expert in Beijing told reporters from the Economic Information Daily on February 1st. Despite the transaction plan incorporating investment risk hedging measures, two major risks cannot be underestimated: first, LNP (Lipid Nanoparticle) patents form the core bottleneck in the industrialization of mRNA technology, and these patents are held by international giants such as Canada-based Arbutus Biopharma; if Nameixin fails to break through these patent barriers, the entire investment rationale ...

• Source: drugdu
• 69
• February 6, 2026

【EXPERT Q&A】Can the registration and access of medical device products in Brazil be accelerated if they already have FDA and CE certifications?

Drugdu.com expert’s response:   Medical devices that have obtained FDA and CE certifications can expedite registration and market access in Brazil, primarily reflected in simplified review processes, reduced redundant testing, and shortened approval cycles. The specific acceleration mechanisms and operational points are as follows: I. Acceleration Mechanisms: ANVISA’s Recognition of International Certifications The Brazilian National Health Surveillance Agency (ANVISA) explicitly allows referencing international authoritative certification results (e.g., FDA, CE) to streamline registration processes. According to ANVISA’s IN 290/2024 directive: 1. Technical Document Mutual Recognition If a product has obtained FDA or CE certification, ANVISA may directly adopt its technical evaluation results (e.g., design validation, performance testing, biocompatibility), minimizing redundant reviews. For example, clinical data and risk assessment reports (ISO 14971) from CE certification can be directly used to support Brazilian registration, avoiding resubmission. 2. On-Site Audit Exemption For Class III and IV high-risk devices, if a company holds an MDSAP (Medical ...

• Source: drugdu
• 63
• February 6, 2026